WINTON GROUP Ltd Makes New $255,000 Investment in Integra LifeSciences Holdings Co. (NASDAQ:IART)

WINTON GROUP Ltd bought a new position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IARTGet Rating) during the second quarter, Holdings Channel reports. The fund bought 4,721 shares of the life sciences company’s stock, valued at approximately $255,000.

A number of other institutional investors also recently bought and sold shares of IART. Steward Partners Investment Advisory LLC raised its stake in Integra LifeSciences by 73.7% during the first quarter. Steward Partners Investment Advisory LLC now owns 707 shares of the life sciences company’s stock worth $45,000 after purchasing an additional 300 shares during the period. First Horizon Advisors Inc. purchased a new stake in shares of Integra LifeSciences in the 2nd quarter valued at approximately $54,000. Covestor Ltd raised its stake in shares of Integra LifeSciences by 63.0% in the 1st quarter. Covestor Ltd now owns 1,558 shares of the life sciences company’s stock valued at $100,000 after acquiring an additional 602 shares during the period. Captrust Financial Advisors raised its stake in shares of Integra LifeSciences by 95.0% in the 1st quarter. Captrust Financial Advisors now owns 2,003 shares of the life sciences company’s stock valued at $129,000 after acquiring an additional 976 shares during the period. Finally, Parametrica Management Ltd purchased a new stake in shares of Integra LifeSciences in the 1st quarter valued at approximately $215,000. 87.33% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Trading Up 2.7 %

NASDAQ IART opened at $53.36 on Monday. The company has a quick ratio of 2.91, a current ratio of 3.93 and a debt-to-equity ratio of 0.86. Integra LifeSciences Holdings Co. has a 52 week low of $40.67 and a 52 week high of $69.95. The stock has a market capitalization of $4.46 billion, a PE ratio of 25.90, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. The firm has a 50 day moving average of $46.51 and a two-hundred day moving average of $52.29.

Analysts Set New Price Targets

A number of research firms have recently issued reports on IART. Truist Financial reduced their price target on shares of Integra LifeSciences from $60.00 to $46.00 and set a “hold” rating on the stock in a research note on Monday, October 17th. StockNews.com began coverage on shares of Integra LifeSciences in a research note on Wednesday, October 12th. They issued a “buy” rating on the stock. Morgan Stanley boosted their price target on shares of Integra LifeSciences from $49.00 to $50.00 and gave the company an “equal weight” rating in a research note on Thursday, October 27th. Jefferies Financial Group assumed coverage on shares of Integra LifeSciences in a research note on Tuesday, October 11th. They set a “hold” rating and a $48.00 target price on the stock. Finally, Citigroup cut their target price on shares of Integra LifeSciences from $57.00 to $50.00 in a research note on Wednesday, October 5th. One research analyst has rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Integra LifeSciences has an average rating of “Hold” and an average target price of $57.38.

About Integra LifeSciences

(Get Rating)

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services.

Further Reading

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Co. (NASDAQ:IARTGet Rating).

Institutional Ownership by Quarter for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.